Bionomics Approves The Proposed Scheme Of Arrangement In Relation To The Company's Proposed Re-Domiciliation From Australia To The U.S., Under Which Neuphoria Therapeutics, Will Become The Ultimate Parent Company Of Bionomics
Bionomics Approves The Proposed Scheme Of Arrangement In Relation To The Company's Proposed Re-Domiciliation From Australia To The U.S., Under Which Neuphoria Therapeutics, Will Become The Ultimate Parent Company Of Bionomics
Bionomics Limited (NASDAQ:BNOX) ("Bionomics" or the "Company") is pleased to provide the following update on the status of its proposed re-domiciliation from Australia to the United States.
Bionomics Limited (納斯達克:BNOX) ("Bionomics"或"公司")很高興提供關於其擬從澳洲遷移到美國的最新進展。
Bionomics shareholders have today approved, by the requisite majority, the proposed Scheme of Arrangement in relation to the Company's proposed re-domiciliation from Australia to the United States, under which Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria"), will become the ultimate parent company of Bionomics Limited following the implementation of the Scheme of Arrangement.
Bionomics的股東今天已按必要多數批准了與公司擬從澳洲重新遷移至美國相關的安排計劃，根據該計劃，德拉瓦州公司Neuphoria Therapeutics Inc.（"Neuphoria"）將在安排計劃實施後成爲Bionomics Limited的最終母公司。
